Spain's First Biotech VC
This article was originally published in Start Up
Executive Summary
Signs are that Spanish biotech, until now held back by a lack of capital and management expertise, may be about to receive the kick-start it badly needs. Newly-created Ysios Capital Partners is the country's first specialist VC. It's raising a first fund worth €65 million ($92 million)--and it's not alone.
You may also be interested in...
European Cell Therapy Players TiGenix And Cellerix Join Forces For Critical Mass, Cash
Lacking critical mass individually, Belgium's TiGenix and Spain's Cellerix have joined forces, attracting €33 million in new investment.
European Cell Therapy Players TiGenix And Cellerix Join Forces For Critical Mass, Cash
Lacking critical mass individually, Belgium's TiGenix and Spain's Cellerix have joined forces, attracting €33 million in new investment.
VCs Eye Europe's Drug Cabinet: Index, Orion Share Designs on Clinical Stage Compounds
Two new investment vehicles have been formed to take advantage of the relative immaturity of Europe's life sciences industry. Index Ventures and Orion Health Care Equity Partners both see opportunities abound in Europe's biopharmaceutical start-ups, but they have different approaches.